Valuation Gilead Sciences, Inc.

Stocks

Real-time Estimate Cboe BZX Other stock markets 07:15:25 28/07/2026 pm IST			5-day change	1st Jan Change
134.74 ^USD	+3.24%		-2.02%	+6.34%

05:59pm	Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial	MT
05:31pm	Barclays Adjusts Gilead Sciences Price Target to $145 From $155, Maintains Equalweight Rating	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	91,081	1,07,677	1,00,942	1,15,118	1,52,281	1,62,050	-	-
Change	-	18.22%	-6.25%	14.04%	32.28%	6.41%	-	-
Enterprise Value (EV) ¹	1,18,530	1,26,522	1,18,665	1,31,838	1,69,585	1,71,647	1,62,050	1,52,094
Change	-	6.74%	-6.21%	11.1%	28.63%	1.22%	-5.59%	-6.14%
P/E	14.7x	23.6x	18x	243x	18.1x	-47x	16.5x	15.2x
PBR	4.32x	5.05x	4.48x	5.98x	6.73x	8.25x	6.44x	5.2x
PEG	-	-0.9x	0.8x	-2.7x	0x	0x	-0x	1.66x
Capitalization / Revenue	3.34x	3.95x	3.72x	4x	5.17x	5.33x	5.02x	4.75x
EV / Revenue	4.34x	4.64x	4.38x	4.59x	5.76x	5.64x	5.02x	4.46x
EV / EBITDA	8.12x	8.86x	9.01x	11.7x	10.6x	31.2x	9.03x	8.46x
EV / EBIT	9.45x	10.4x	11.3x	15.5x	12.9x	62x	10.4x	9.09x
EV / FCF	11x	15.2x	16x	12.8x	17.9x	212x	12.2x	10.8x
FCF Yield	9.12%	6.59%	6.25%	7.82%	5.58%	0.47%	8.18%	9.25%
Dividend per Share ²	2.84	2.92	3	3.08	3.16	3.296	3.409	3.102
Rate of return	3.91%	3.4%	3.7%	3.33%	2.57%	2.53%	2.61%	2.38%
EPS ²	4.93	3.64	4.5	0.38	6.78	-2.775	7.887	8.608
Distribution rate	57.6%	80.2%	66.7%	811%	46.6%	-119%	43.2%	36%
Net sales ¹	27,305	27,281	27,116	28,754	29,443	30,425	32,297	34,107
EBITDA ¹	14,598	14,283	13,177	11,287	15,953	5,510	17,953	17,972
EBIT ¹	12,548	12,180	10,484	8,520	13,193	2,771	15,584	16,737
Net income ¹	6,225	4,592	5,665	480	8,510	-3,391	9,779	10,495
Net Debt ¹	27,449	18,845	17,723	16,720	17,304	9,597	-	-9,955
Reference price ²	72.61	85.85	81.01	92.37	122.74	130.52	130.52	130.52
Nbr of stocks (in thousands)	12,54,384	12,54,244	12,46,042	12,46,266	12,40,680	12,41,570	-	-
Announcement Date	01/02/22	02/02/23	06/02/24	11/02/25	10/02/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
GILEAD SCIENCES, INC.	-47.03x	5.64x	31.15x	2.53%	16TCr
ELI LILLY AND COMPANY	35.56x	12.7x	26.67x	0.56%	1,06800Cr
JOHNSON & JOHNSON	28.51x	6.52x	18.04x	2.02%	64TCr
ABBVIE INC.	32.33x	7.59x	15.6x	2.68%	45TCr
ROCHE HOLDING AG	19.49x	4.75x	11.79x	2.78%	35TCr
NOVARTIS AG	22.29x	5.76x	14.37x	2.78%	30TCr
ASTRAZENECA PLC	21.47x	4.5x	12.72x	1.93%	27TCr
NOVO NORDISK A/S	14.4x	5.35x	11.02x	3.48%	22TCr
AMGEN INC.	24.71x	6.49x	11.44x	2.68%	20TCr
PFIZER INC.	12.52x	3.08x	7.78x	6.98%	14TCr
Average	16.43x	6.24x	16.06x	2.84%	38.04TCr
Weighted average by Cap.	24.31x	7.78x	18.36x	2.14%